Glucocorticoid-induced osteoporosis: an update

Area of Science:

• Endocrinology
• Bone Biology
• Pharmacology

Background:

• Glucocorticoid-induced osteoporosis is a leading secondary cause of osteoporosis.
• Rapid bone loss and increased fracture risk occur soon after initiating glucocorticoids, dose-dependently.
• Adverse effects stem from inhibited bone formation and transiently increased bone resorption.

Purpose of the Study:

• To outline the mechanisms of glucocorticoid-induced bone loss.
• To emphasize timely fracture risk assessment and intervention.
• To compare treatment options for glucocorticoid-induced osteoporosis.

Main Methods:

• Review of mechanisms affecting bone remodeling, including molecular pathways (PPARγR2, sclerostin, RANKL/OPG ratio) and systemic factors (hypogonadism, calcium handling, IGF-1).
• Discussion of clinical guidelines for fracture risk assessment and management.
• Comparison of therapeutic efficacy of oral bisphosphonates and teriparatide.

Main Results:

• Glucocorticoids induce osteoporosis through complex mechanisms impacting bone formation and resorption.
• Early intervention with bone-protective agents is recommended for high-risk individuals.
• Teriparatide demonstrates superior effects on bone mineral density and vertebral fracture risk compared to bisphosphonates in this population.

Conclusions:

• Prompt fracture risk assessment and bone-protective therapy are essential upon glucocorticoid initiation.
• Oral bisphosphonates are cost-effective first-line treatments.
• Teriparatide is a superior alternative first-line option for high-risk patients due to its efficacy in improving BMD and reducing vertebral fractures.